FC enters May with short sellers firmly on the back foot — a massive earnings-day squeeze last month has triggered one of the sharpest covering episodes of the past year, and the institutional register just changed hands in a meaningful way.
The headline story is the unwind. Short interest has dropped 36% over the past month, falling from roughly 1.68 million shares in early April to around 1.0 million now. The trigger was the Q2 fiscal 2026 results on April 1, when the stock jumped nearly 48% in a single session and held most of that gain through the week. That kind of move forces covering — and the data confirms it happened quickly. Estimated short interest as a percentage of the free float now registers at 8.3%, down from levels above 14–15% seen through most of mid-April before the bulk of the covering hit. The ORTEX short score has mirrored this, sliding from 68.5 in mid-April to 62.3 this week — still elevated, but the direction of travel is clear.
The borrow market has relaxed accordingly. Cost to borrow has eased to 0.59%, a 30-day low, down roughly 15% from its early-April peak. That level signals no scarcity of supply for those still running short positions. The covering wave has also pushed availability wider, with the lending pool now far less strained than it was during late March and early April when borrow conditions were tightest. Options positioning reinforces the calmer mood: the put/call ratio at 2.31 is actually slightly below its 20-day average of 2.77, making this week's configuration somewhat less defensive than has been typical for this name — a notable contrast to the hedging frenzy seen in early April when the PCR touched its 52-week high near 3.73.
The Street is constructive, though not loudly so. Coverage of FC is thin — two analysts on record, both with buy-equivalent ratings. Barrington Research's standing target of $25 was set in January, and the current price at $21.63 after the pullback this week (down 5.4% over five sessions) means the stock trades below that target despite the 41% one-month gain. A mean target of $28.33 implies roughly 31% upside from here. The bull case rests on deferred subscription revenue up 7.5% year-on-year and international segment growth of 7%, suggesting future revenue recognition that hasn't yet shown up in reported figures. The bear argues that total revenue fell 7.3% in Q1, gross margins compressed 160 basis points to 61.6%, and the Enterprise Division — the largest revenue contributor — has now posted two consecutive quarters of decline. Adjusted EBITDA swung to a loss of $1 million from a prior-year gain of $0.3 million. EPS momentum tells a more encouraging story: the 30-day momentum factor ranks in the 91st percentile, and the 90-day figure is nearly as strong at the 89th percentile.
The most structurally interesting development this week sits in the ownership table. Royce & Associates added 593,626 shares in Q1, lifting its stake to 1.04 million shares — a position that now represents 9.2% of the company. That's a significant accumulation for a small-cap name with a market cap in this range. AllianceBernstein remains the largest holder at 10.1% of shares, while BlackRock added 115,264 shares to reach 8.7%. Chairman Robert Whitman trimmed 21,897 shares in early April — a modest reduction logged on April 7, the week after the earnings pop — but retains a 6% stake. The overall net insider position for the 90-day window to November 2025 (the most recently available data) showed net buying of roughly $560,000, though that data is now stale at 160 days and should be treated as background context rather than a current signal.
The next earnings event is June 24. With the stock having retraced roughly 12% from its post-results peak, the question heading into that date is whether the deferred revenue pipeline converts as expected — or whether the Q1 revenue decline and margin pressure prove more persistent than the April reaction implied.
See the live data behind this article on ORTEX.
Open FC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
